Mold & Mycotoxin Illness: A Comprehensive Guide to Diagnosis, Detox, and Recovery

When the Building Makes You Sick

Mold illness is one of the most underdiagnosed and misunderstood conditions in modern medicine. Millions of people live and work in water-damaged buildings without realizing that the invisible microbial ecosystem thriving in those walls — molds, bacteria, actinomycetes, and their toxic byproducts — is systematically dismantling their health. The result is a constellation of symptoms so diverse and seemingly unrelated that most patients spend years cycling through specialists, collecting diagnoses of fibromyalgia, chronic fatigue syndrome, anxiety, depression, and autoimmune disease, before anyone considers the environment as the root cause.

Mycotoxins — the toxic secondary metabolites produced by mold species — are among the most potent biological toxins on earth. Aflatoxin B1, produced by Aspergillus species, is the most potent naturally occurring carcinogen known. Ochratoxin A, produced by Aspergillus and Penicillium species, is nephrotoxic, immunosuppressive, and neurotoxic. Trichothecenes, produced by Stachybotrys chartarum (the infamous black mold), are so toxic they have been investigated as biological warfare agents. These are not benign substances — and for genetically susceptible individuals, chronic low-level exposure is sufficient to trigger a cascade of systemic inflammation that does not resolve on its own.

This guide covers the biology of mold illness, the diagnostic framework developed by Dr. Ritchie Shoemaker, the evidence-based treatment protocol, and the nutritional and supplemental strategies that support recovery.

The Biology of Mold Illness: Why Some People Get Sick and Others Don't

Approximately 25% of the population carries HLA-DR gene variants that impair the immune system's ability to recognize and tag biotoxins for elimination. In healthy individuals with normal HLA-DR variants, mycotoxins are identified by the innate immune system, bound to antibodies, and cleared through normal detoxification pathways. In genetically susceptible individuals, this recognition step fails — mycotoxins are not properly tagged, and instead of being eliminated, they recirculate continuously through the body, triggering an unrelenting inflammatory response.

This is the core mechanism of Chronic Inflammatory Response Syndrome (CIRS) — the clinical framework developed by Dr. Ritchie Shoemaker to describe the multi-system, multi-symptom illness that results from biotoxin exposure in genetically susceptible individuals. CIRS is not an allergy and it is not a mold infection — it is a dysregulated innate immune response driven by biotoxins that the body cannot clear.

The inflammatory cascade triggered by recirculating mycotoxins affects virtually every system in the body. Elevated cytokines (particularly TGF-beta-1, MMP-9, and C4a) drive systemic inflammation. Disrupted MSH (melanocyte-stimulating hormone) impairs sleep, pain regulation, gut motility, and immune function. Elevated VEGF disrupts capillary blood flow. Dysregulated ADH causes osmotic instability. Leptin resistance drives fatigue and weight gain. The result is a patient who is sick in ways that defy simple categorization — and whose labs often appear normal on standard testing.

Symptoms of Mold and Mycotoxin Illness

The symptom profile of CIRS is notoriously broad. The Shoemaker cluster analysis identified 37 symptoms across 13 clusters that are statistically associated with biotoxin illness. No single symptom is diagnostic, but the pattern — particularly when multiple clusters are affected simultaneously — is highly characteristic.

Neurological and cognitive: Brain fog, memory impairment, difficulty concentrating, word-finding problems, disorientation, confusion, and cognitive decline that worsens in water-damaged environments.

Fatigue and post-exertional malaise: Profound, unrefreshing fatigue that does not improve with rest and worsens significantly after physical or cognitive exertion — a pattern that distinguishes CIRS from simple deconditioning.

Pain: Widespread muscle aches, joint pain without swelling, ice-pick headaches, and unusual sensitivity to light touch (allodynia).

Respiratory: Chronic cough, shortness of breath, air hunger, sinus congestion, and recurrent respiratory infections.

Gastrointestinal: Abdominal pain, nausea, diarrhea, and appetite changes — driven by MSH disruption and gut motility dysfunction.

Autonomic and vascular: Temperature dysregulation, excessive thirst, frequent urination, static shocks, and unusual sensitivity to light and sound.

Psychiatric: Anxiety, depression, mood instability, and in severe cases, psychosis — driven by neuroinflammation and disrupted neurotransmitter metabolism.

A key diagnostic clue is environmental reactivity — symptoms that worsen in specific buildings and improve when the patient leaves. Many CIRS patients report feeling significantly better on vacation or when traveling, only to relapse immediately upon returning home or to work.

Diagnosis: The Shoemaker Protocol Testing Framework

Diagnosing mold illness requires a systematic approach that combines symptom assessment, objective biomarkers, visual contrast sensitivity testing, and environmental investigation. No single test is sufficient — the diagnosis is made by the convergence of multiple data streams.

Visual Contrast Sensitivity (VCS) Testing

The VCS test measures the ability to detect contrast between shades of grey at varying spatial frequencies. Biotoxins impair the function of the retinal ganglion cells responsible for contrast detection, producing a characteristic pattern of VCS failure that is present in approximately 92% of CIRS patients. The test is available online at survivingmold.com and takes approximately 10 minutes. A positive VCS test is not diagnostic on its own but is a powerful screening tool — a negative VCS test makes CIRS significantly less likely.

HLA-DR Genetic Testing

HLA-DR typing identifies whether the patient carries susceptibility variants associated with impaired biotoxin clearance. The most common susceptibility haplotypes include 4-3-53, 11-3-52B, and 14-5-52B. Approximately 25% of the general population carries at least one susceptibility haplotype. HLA-DR testing is available through LabCorp and Quest and is typically ordered as part of a comprehensive CIRS workup.

Inflammatory Biomarkers

The Shoemaker protocol uses a panel of biomarkers that reflect the specific inflammatory pathways activated in CIRS. Key markers include TGF-beta-1 (elevated in most CIRS patients, reflecting ongoing innate immune activation), C4a (a complement split product that is dramatically elevated in active biotoxin illness), MMP-9 (a matrix metalloproteinase that drives tissue inflammation and is elevated in CIRS), MSH (melanocyte-stimulating hormone, which is low in most CIRS patients and drives the majority of downstream symptoms), VEGF (vascular endothelial growth factor, which is dysregulated in CIRS and impairs capillary perfusion), ADH and osmolality (reflecting the osmotic dysregulation common in CIRS), and VIP (vasoactive intestinal polypeptide, which is low in advanced CIRS and drives autonomic dysfunction).

Mycotoxin Urine Testing

Urine mycotoxin testing directly measures the presence of specific mycotoxins being excreted by the body. The most clinically validated panels are offered by RealTime Laboratories and Great Plains Laboratory (now Mosaic Diagnostics). These panels test for aflatoxins, ochratoxin A, trichothecenes, zearalenone, and other clinically relevant mycotoxins. Positive results confirm mycotoxin exposure and help guide targeted treatment. It is important to note that mycotoxin testing reflects current excretion, not total body burden — patients who are poor excretors may have significant tissue accumulation with relatively low urine levels.

Environmental Testing: ERMI and HERTSMI-2

The Environmental Relative Moldiness Index (ERMI) is a DNA-based dust test that quantifies the presence of 36 mold species in a home or workplace. The HERTSMI-2 is a simplified version focusing on the five species most associated with CIRS: Stachybotrys chartarum, Aspergillus penicillioides, Aspergillus versicolor, Chaetomium globosum, and Wallemia sebi. An ERMI score above 2 or a HERTSMI-2 score above 11 indicates a building that is likely to cause illness in susceptible individuals. Environmental testing is essential — treatment cannot succeed if the patient remains in a moldy environment.

The Shoemaker Protocol: A Step-by-Step Treatment Framework

The Shoemaker protocol is a sequential, evidence-based treatment framework that addresses each step of the CIRS pathophysiology in order. Skipping steps or treating out of sequence significantly reduces efficacy.

Step 1: Remove from Exposure

No treatment will work if the patient remains in a water-damaged building. The first and most critical step is identifying and eliminating the source of exposure. This may mean remediating the home, relocating temporarily, or changing workplaces. For patients with severe sensitivity, even brief re-exposure to a moldy environment can reset months of treatment progress. This step is non-negotiable.

Step 2: Binders — Sequestering Mycotoxins in the Gut

Mycotoxins undergo enterohepatic recirculation — they are processed by the liver, excreted into bile, and reabsorbed in the small intestine, perpetuating the toxic cycle. Binders interrupt this cycle by binding mycotoxins in the gut and preventing reabsorption, allowing them to be excreted in stool.

Cholestyramine (CSM) is the most studied binder for CIRS and remains the gold standard in the Shoemaker protocol. It is a bile acid sequestrant that binds mycotoxins with high affinity. Typical dosing is 4 grams four times daily, taken away from food and medications. CSM requires a prescription and can cause constipation, which must be managed proactively.

Welchol (colesevelam) is a second-generation bile acid sequestrant that is better tolerated than CSM and is used for patients who cannot tolerate cholestyramine. It is less potent but significantly more convenient.

Natural binders including activated charcoal, bentonite clay, zeolite, and modified citrus pectin are widely used as adjuncts or alternatives for patients who cannot access prescription binders. Activated charcoal is particularly effective for trichothecenes and aflatoxins. These binders should be taken away from food, supplements, and medications to avoid interfering with nutrient absorption.

Step 3: Eradicating MARCoNS

MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) is a deep nasal biofilm infection found in approximately 80% of CIRS patients with low MSH. MARCoNS produces exotoxins that further suppress MSH and perpetuate the inflammatory cycle. It is identified by a deep nasal culture (not a standard nasal swab) and treated with BEG nasal spray — a compounded preparation of Bactroban (mupirocin), EDTA, and gentamicin — used twice daily for 30 days. Eradicating MARCoNS is essential before MSH can recover.

Step 4: Correcting Downstream Hormonal and Inflammatory Abnormalities

Once binders are working and MARCoNS is eradicated, the protocol addresses the specific biomarker abnormalities identified in testing. Elevated TGF-beta-1 is treated with losartan. Elevated MMP-9 is addressed through dietary modification (eliminating amylose — high-glycemic foods) and fish oil. Low VEGF may require treatment with VIP nasal spray. Low ADH is managed with DDAVP. Each step is guided by repeat biomarker testing to confirm normalization before proceeding.

Step 5: VIP (Vasoactive Intestinal Polypeptide)

VIP is a neuropeptide that regulates inflammation, autonomic function, and immune balance. It is low in most advanced CIRS patients and is the final step in the Shoemaker protocol. VIP nasal spray is a compounded preparation used four times daily and has been shown to normalize multiple downstream biomarkers, improve exercise tolerance, and resolve many residual symptoms. VIP should only be used after the patient has been confirmed out of exposure and MARCoNS has been eradicated — using VIP in an active mold environment can cause significant worsening.

Nutritional and Supplemental Support for Mold Recovery

While the Shoemaker protocol addresses the core pathophysiology of CIRS, targeted nutritional support plays an important complementary role in supporting detoxification, reducing inflammation, protecting against oxidative damage, and rebuilding the systems that mycotoxin illness has depleted.

Glutathione

Glutathione is the body's master antioxidant and the primary intracellular defense against mycotoxin-induced oxidative stress. Mycotoxins — particularly aflatoxins and trichothecenes — deplete glutathione rapidly, leaving cells vulnerable to oxidative damage. Supplemental glutathione (liposomal or S-acetyl forms for best absorption), N-acetylcysteine (NAC, the rate-limiting precursor to glutathione synthesis), and alpha-lipoic acid (which regenerates glutathione) are foundational supports for mold recovery. Some CIRS patients experience detox reactions when starting glutathione — starting low and increasing gradually is advisable.

Activated Charcoal and Binders

As noted above, activated charcoal is a powerful natural binder for mycotoxins. It is most effective when taken on an empty stomach, away from food and supplements. Bentonite clay and zeolite provide complementary binding activity through different mechanisms. Rotating binders can improve coverage across different mycotoxin classes.

Magnesium

Magnesium deficiency is nearly universal in CIRS patients. Mycotoxins impair magnesium absorption and increase urinary magnesium excretion. Magnesium is required for over 300 enzymatic reactions including ATP production, neurotransmitter synthesis, and detoxification enzyme function. Magnesium glycinate or malate (400 to 600 mg daily) is well tolerated and supports energy, sleep, muscle function, and nervous system regulation throughout recovery.

Omega-3 Fatty Acids

High-dose omega-3 supplementation (EPA + DHA, 2 to 4 grams daily) reduces MMP-9, lowers systemic inflammation, supports neurological repair, and improves mood — all of which are relevant to CIRS recovery. Omega-3s also support the integrity of cell membranes that mycotoxins damage through lipid peroxidation.

Vitamin D3 + K2

Vitamin D deficiency is common in CIRS patients and impairs immune regulation, increases susceptibility to infections, and worsens the inflammatory response. Optimal 25-OH Vitamin D for CIRS recovery is 60 to 80 ng/mL. Vitamin K2 (MK-7 form) is essential alongside D3 to direct calcium appropriately and prevent soft tissue calcification at higher D3 doses.

Probiotics and Gut Support

Mycotoxins are profoundly damaging to the gut microbiome — they kill beneficial bacteria, promote fungal overgrowth, increase intestinal permeability, and impair gut motility. Restoring gut integrity is essential for recovery. A high-quality, multi-strain probiotic (Lactobacillus and Bifidobacterium species), combined with prebiotic fiber and gut-healing nutrients (L-glutamine, zinc carnosine, colostrum), supports microbiome restoration and reduces the gut inflammation that perpetuates systemic CIRS symptoms.

B Vitamins (Methylated)

Mycotoxins impair methylation — the biochemical process essential for detoxification, neurotransmitter synthesis, DNA repair, and immune function. Many CIRS patients also carry MTHFR polymorphisms that further compromise methylation capacity. Methylated B vitamins (methylfolate, methylcobalamin, P5P) bypass the impaired MTHFR enzyme and directly support methylation, homocysteine clearance, and neurological repair.

The Amylose-Free Diet in CIRS

The Shoemaker protocol recommends an amylose-free diet during active treatment. Amylose is a type of starch found in high-glycemic foods including bread, pasta, rice, potatoes, and corn. Elevated amylose intake raises MMP-9 and worsens systemic inflammation in CIRS patients. The amylose-free diet emphasizes non-starchy vegetables, quality proteins, healthy fats, and low-glycemic fruits. This dietary approach also reduces fungal overgrowth by eliminating the sugars that feed Candida and other opportunistic fungi that commonly colonize CIRS patients.

Mold Remediation: What Works and What Doesn't

Effective mold remediation requires professional assessment and intervention — not bleach, paint-over, or air fresheners. Key principles include identifying and fixing the water source (without which remediation will always fail), physical removal of contaminated materials (drywall, insulation, carpet, wood), HEPA air filtration during and after remediation, and post-remediation verification testing (ERMI or HERTSMI-2) to confirm the building is safe before re-entry.

For patients with severe sensitivity, even a successfully remediated building may retain enough residual mycotoxin contamination in furnishings, clothing, and HVAC systems to perpetuate illness. In these cases, a fresh start in a new environment — with new belongings — may be necessary for recovery. This is a difficult reality that must be addressed honestly with patients who are not improving despite treatment.

Recovery: What to Expect

Recovery from mold illness is real but rarely linear. Most patients begin to notice improvement within 4 to 8 weeks of starting binders and leaving the moldy environment. Cognitive symptoms often improve first, followed by energy and pain. Full recovery — defined as normalization of biomarkers and resolution of symptoms — typically takes 6 to 24 months depending on the duration and severity of exposure, the presence of MARCoNS, and the patient's genetic susceptibility profile.

Setbacks are common and should be anticipated. Re-exposure to even small amounts of mold can trigger significant symptom flares. Stress, infections, and poor sleep all worsen CIRS symptoms. Patience, consistency with the protocol, and a knowledgeable practitioner are the most important factors in successful recovery.

Related Reading

• Autoimmune Disease: An Integrative Approach
• Chronic Pain: An Integrative Approach
• Liver Detox: Supporting Your Body's Master Detoxifier

References

1. Shoemaker RC, House DE. Sick Building Syndrome (SBS) and Exposure to Water-Damaged Buildings. Neurotoxicology and Teratology. 2006;28(5):573-588.
2. Shoemaker RC, et al. Residential and Recreational Acquisition of Possible Estuary-Associated Syndrome. Environmental Health Perspectives. 2001;109(Suppl 5):791-796.
3. Bennett JW, Klich M. Mycotoxins. Clinical Microbiology Reviews. 2003;16(3):497-516.
4. Brewer JH, et al. Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome. Toxins. 2013;5(4):605-617.
5. Thrasher JD, Crawley S. The Biocontaminants and Complexity of Damp Indoor Spaces. Toxicology and Industrial Health. 2009;25(9-10):583-615.
6. Shoemaker RC, House D, Ryan JC. Structural Brain Abnormalities in Patients with Inflammatory Illness Acquired Following Exposure to Water-Damaged Buildings. Neurotoxicology and Teratology. 2014;45:18-26.
7. Pizzorno J. Glutathione! Integrative Medicine. 2014;13(1):8-12.
8. Sordillo PP, Helson L. Curcumin and Cancer Stem Cells: Curcumin Has Asymmetrical Effects on Cancer and Normal Stem Cells. Anticancer Research. 2015;35(2):599-614.